Shang Hai Zheng Quan Bao·2025-08-14 19:17Core Viewpoint - The major shareholder, Shanghai Tan Ying Investment Partnership, plans to reduce its stake in Junshi Biosciences by up to 20,533,797 shares, representing a maximum of 2% of the company's total equity, due to fund liquidity arrangements [2][12]. Shareholder Information - As of the announcement date, Shanghai Tan Ying holds 71,459,326 shares of Junshi Biosciences, accounting for 6.9602% of the total share capital [1][12]. - The shares were acquired prior to the company's IPO and have been tradable since July 15, 2021 [1]. Reduction Plan Details - The reduction will be executed through block trading, with the total number of shares sold not exceeding 2% of the total equity within any continuous 60-day period, starting 15 trading days after the announcement [2][12]. - The selling price will be determined based on market conditions, and adjustments will be made if corporate actions such as dividends or stock splits occur during the reduction period [2][12]. Compliance and Commitments - Shanghai Tan Ying has made commitments regarding shareholding and reduction, including a promise not to transfer shares within 12 months post-IPO and to comply with relevant regulations during the holding period [6][8]. - The shareholder has also committed to announce any reduction plans three trading days in advance and to ensure that the selling price does not fall below the IPO price adjusted for any corporate actions [8][9]. Regulatory Compliance - The reduction plan complies with various regulations, including the Securities Law of the People's Republic of China and the Shanghai Stock Exchange's rules, and does not pose a risk of changing the company's control [12][13].